Posted on January 22nd, 2024. Posted by Jack Powell
With the J.P. Morgan Healthcare Conference behind us, now is the ideal time to opine on what the future holds for the MedTech sub-sector in 2024.
See below for several thoughts and key takeaways on the general sentiment and outlook for MedTech this year. This is my personal view, which has been informed in part by a review of outlook-focused, long-form research from nearly two dozen MedTech sell-side analysts, discussions with many of the top institutional investors in healthcare, and (seemingly countless) meetings with investors, analysts, bankers and clients during the week of the J.P. Morgan Conference. Continue Reading
Posted on January 15th, 2024. Posted by Mark Corbae
Artificial Intelligence (AI), instrumental in many healthcare trends of 2023, promises to dramatically gain momentum in 2024, with increased use of transformative technologies that have applications across the healthcare industry, from the way pharmaceuticals are developed and patients are treated to the commercial side of the business.
AI is already used in healthcare for end-to-end drug development, helping to diagnose patients, improving physician-to-patient communication, transcribing and organizing medical files and images, and treating patients remotely. Continue Reading
Posted on November 16th, 2023. Posted by ICR Westwicke
Each year, the J.P. Morgan Healthcare Conference provides a critical opportunity to meet with analysts, investors, and other leaders in the healthcare industry. However, making the most of the conference takes preparation.
Continue Reading
Posted on November 14th, 2023. Posted by Kate Coyle
In less than two months, seasoned investors, influential media, game changing startups and established industry giants will convene at the 42nd Annual JP Morgan Healthcare Conference. Continue Reading
Posted on September 29th, 2023. Posted by Bob East
Properly positioning your story within the investment community can help you build a quality, long-term shareholder base and enhance equity market value. To develop an effective investor relations strategy, you must understand how to best interact with investors, stay visible, and adapt to deliver both good news and bad.
Continue Reading
Posted on June 26th, 2023. Posted by Asher Dewhurst
Some management teams assume — incorrectly — that they can play it safe by withholding financial guidance, believing they can’t miss estimates they don’t provide. To the contrary, companies may inadvertently limit their Street credibility by opting out of earnings forecasts and, at the same time, miss an opportunity to manage investor expectations.
Investors judge financial results against analysts’ consensus estimates even if a company doesn’t provide projection, so it makes sense for leadership to set expectations themselves and provide some guardrails. Perhaps more importantly, formal earnings guidance signals management’s confidence in the company’s growth and stability.
Continue Reading
Posted on June 20th, 2023. Posted by Mark Corbae
Any company, no matter how diligent, can find itself suddenly thrust into a crisis due to internal or external factors. Incidents ranging from a product safety recall to a downturn in industry funding or worldwide health emergency have the potential to disrupt operations or threaten a company’s reputation. Stakeholders, whether customers, shareholders, partners or employees, will want to know immediately what happened and how it affects them. In today’s age of social media and instantaneous digital communication, companies need to be prepared to address a crisis immediately before someone else defines what it means for their stakeholders.
Continue Reading
Posted on May 18th, 2023. Posted by Megan Kernan
The American Society of Clinical Oncology (ASCO) Annual Meeting provides a unique opportunity to connect with oncology professionals, major media outlets, and other industry representatives from across the globe. It’s undeniably one of the most important conferences for the oncology community every year.
Continue Reading
Posted on March 21st, 2023. Posted by Ben Shannon
While SVB was the 16th largest U.S. bank and second-largest bank failure in U.S. history before it closed last week, those numbers don’t tell the whole story.
SVB was the bank for tech, biotech, digital health companies and venture capital firms, banking with nearly half of U.S. venture-backed healthcare and tech IPOs, as well as nearly half of venture-backed tech and life sciences companies. It was popular with startups and venture funds because it can be more difficult for early-stage companies to get loans from larger, more established banks. SVB made a point of being seen as a friendly lender to innovative companies.
Continue Reading
Posted on March 15th, 2023. Posted by Ben Shannon
In May, the COVID-19 Public Health Emergency (PHE) that was officially declared more than three years ago will officially end. COVID-19 has killed about 1.1 million Americans and is still responsible for the deaths of between 2,500 and 3,500 Americans every week.
Continue Reading
